ArticleAmerican journal of translational research2023
Efficacy of ganciclovir in the treatment of cytomegalovirus (CMV) infection in infants and its effect on inflammatory reaction and immune function.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Detection of Cytomegalovirus in Patients Attending a Tertiary Care Center: A Retrospective Analysis.Cureus · 2026Article
- Immunometabolic crossroads: infections as bidirectional modulators in diabetes and metabolic syndromes.Frontiers in endocrinology · 2025Review
- Cytomegalovirus-associated pancytopenia in a four-month-old infant: a case report.BMC infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy of ganciclovir in the treatment of cytomegalovirus (CMV) infection in infants and its effect on inflammatory reaction and immune function.
methodsIn this retrospective analysis, from January 2019 to December 2022, a total of 100 infants with CMV infection were collected from the Department of Pediatrics of Anhui Maternal and Child Health Hospital and divided into two groups (50 in each group) based on differences in intervention methods. The control group (CG) was given routine treatment and antiviral therapy, and the observation group (OG) was additionally given intravenous drip of 5-6 mg/kg ganciclovir on the basis of routine treatment given to the CG. After 21 d of treatment, the clinical efficacy, inflammatory factor levels, immunoglobulin levels, T-lymphocyte levels and incidence of adverse reactions of both groups were observed and compared.
resultsAfter treatment, the overall response rate in the OG (92.00%) was significantly higher than that in the CG (76.00%) (
conclusionIntervention of ganciclovir can effectively treat CMV infection in infants, reduce the inflammatory reactions and enhance the immune function of the body, without increasing the incidence of adverse reactions.
Indexed as
Identifiers
38074833PMC10703652W4389802841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.